Brinter
Brinter is a pioneering US-based MedTech firm focused on revolutionizing tissue engineering through the development of 3D bioprinted biocomposite implants, known as BioMods™, which aim to restore damaged tissue and replace conventional implants. The company is dedicated to health equality and ethical advances in healthcare, driven by a team of visionary entrepreneurs and leading bioscientists and engineers.
What We Do
3D Bioprinted Biocomposite Implants
Brinter develops 3D bioprinted biocomposite implants, or BioMods™, offering superior alternatives to human tissue repairs. These implants are designed for various surgical applications, including orthopedics and sports medicine, and are 100% resorbable.
Advanced Regenerative Medicine
The company focuses on advanced regenerative medicine, utilizing its proprietary technology to accelerate tissue regeneration and improve healthcare outcomes.
Brinter ONE
A powerful modular 3D bioprinter designed for commercial manufacturing of biocomposite implants, offering variable printing modalities and low manufacturing costs.
Brinter CORE
A compact 3D bioprinter for research and development of biocomposite implants, featuring a modular design and variable printing modalities.
Application Area
News & Updates
The Brinter team, including CEO Tom Alapaattikoski and CSO Matthew Brovold, will attend the prestigious BIO International Convention in San Diego, focusing on advancing their BioMod technology.
Brinter is set to participate in the Biocom California’s Converge Summit on May 22, 2024, to engage with industry leaders and explore emerging trends in tech and healthcare.